Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With SLE
Latest Information Update: 07 Nov 2021
At a glance
- Drugs INV 103 (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Sponsors Invion
- 08 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Aug 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 13 Apr 2015 Planned End Date changed from 1 Apr 2015 to 1 Oct 2015, according to to ClinicalTrials.gov record.